

Idaho Incubation Fund Program

Progress Report Form

Proposal No. IF15-002 (BSU 691A1000419)
Name: Cheryl L. Jorcyk, PhD
Name of Institution: Boise State University
Project Title: Small Molecule Inhibitors for the Reduction of Cancer Metastasis
Reporting Period: December 1, 2014 to June 5, 2015

Information to be reported in your progress report is as follows (attach additional information as needed):

1. Summary of project accomplishments for the period just completed and plans for the coming reporting period:

Our lab has been continuing to develop functional assays. These assays can be used to determine if oncostatin M small molecule inhibitors (OSM-SMIs) will block the functions produced by OSM acting on tumor cells in culture. Most recently, we have developed a tumor cell morphology-based assay that shows that OSM-SMI-8 inhibits the change in morphology associated with OSM-induced breast and prostate tumor cell EMT (epithelial-mesenchymal transition).

Our collaborator, Dr. Don Warner, synthesized three compounds for testing. The first did not show any inhibitory activity. This molecule was a monomer of the original dimer that showed activity. Thus, this result suggests that the entire dimer is important. Future derivatization will focus on the complete dimer. The remaining two compounds were not soluble in aqueous solutions, so these were not tested. Currently, Dr. Warner is preparing 4 soluble analogs that will be tested in due course.

2. Summary of budget expenditures for the period just completed (include project burn rate):

See attached budget report.

3. Numbers of faculty and student participation resulting from the funding, including internships:

Research participants include:

Two Faculty
One PhD Student
One Technician

Drs. Cheryl Jorcyk and Don Warner
Ken Tawara
Daniel Hedeem

**One High School Teacher
Four Undergraduate Students**

**John Doherty
Hannah Scott (Jorcyk)
Katie Neal (Jorcyk)
Carson Kidwell (Warner)
Lauren Hosek (Warner)**

4. List patents, copyrights, plant variety protection certificates received or pending:

One patent application (#P10980US01) entitled “Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders” was submitted 9/5/14.

5. List technology licenses signed and start-up businesses created:

None

6. Status of private/industry partnerships (include enough information to judge level of engagement):

None

7. Any other pertinent information that will indicate to the council that the project is meeting satisfactory progress.

None